Cullinan Therapeutics’ (CGEM) “Overweight” Rating Reaffirmed at Morgan Stanley
Morgan Stanley reissued their overweight rating on shares of Cullinan Therapeutics (NASDAQ:CGEM – Free Report) in a research report sent to investors on Friday,Benzinga reports. They currently have a $35.00 target price on the stock, down from their prior target price of $38.00. Separately, HC Wainwright reaffirmed a “buy” rating and set a $33.00 price […]
Morgan Stanley reissued their overweight rating on shares of Cullinan Therapeutics (NASDAQ:CGEM – Free Report) in a research report sent to investors on Friday,Benzinga reports. They currently have a $35.00 target price on the stock, down from their prior target price of $38.00. Separately, HC Wainwright reaffirmed a “buy” rating and set a $33.00 price […]
